Sirolimus and Mycophenolate Mofetil as Graft Versus Host Disease Prophylaxis in Myeloablative Matched Related Donor Hematopoietic Cell Transplantation
To evaluate the incidence of grade II-IV acute GVHD with sirolimus and mycophenolate mofetil GVHD prophylaxis.
Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.
- drug : Mycophenolate Mofetil
- drug : Sirolimus
Phase: Phase 2
Ages Eligible For Study:
Diagnoses Included: 1. Acute myelogenous leukemia (AML): - Age 2-60 years beyond 2nd remission or relapsed/refractory disease. - Age 51-60 years of age, in first or subsequent remission or relapsed/refractory disease - AML with multilineage dysplasia 2. Acute lymphoblastic leukemia (ALL): - Age 2-60 years beyond 2nd remission or relapsed/refractory disease - Age 51-60 years in first or subsequent remission or relapsed/refractory disease 3. Chronic myelogenous leukemia (CML), beyond 2nd chronic phase or in blast crisis 4. Myelodysplastic syndrome (MDS) including patients with World Health Organization (WHO) refractory anemia with excess blasts-1 (RAEB-1), RAEB-2 and therapy-related MDS 5. Myeloproliferative disorders with poor long- term survival including myeloid metaplasia and myelofibrosis 6. Non-hodgkin lymphoma (NHL) - High risk NHL in first remission - Relapsed or refractory NHL 7. Hodgkin lymphoma beyond first remission Other Inclusion Criteria: 1. Patients 2-60 years of age 2. Matched related donor identified, 6/6 HLA-A, B and DRB1 3. Karnofsky performance status >= 70% or Lansky performance status >= 70% or patients < 16 years old. 4. Willingness and ability to take oral medications in pill form during the transplantation period. 5. Informed consent